May. 15 at 9:38 PM
$CADL I would say after today's abstract and presentation; as the data continues to evolve positively, likelihood of approval has definitely increased. As long as the CMC execution is good I'd now say probably 85% chance this gets approved on first submission, if not a little higher. Assuming strong uptake and payer adoption; 30-40% market penetration could result in
$2.6BN+ in sales for this single indication alone, at
$100K/treatment. You do the math on potential upside based on those #s.
